Alumis Inc. (NASDAQ:ALMS) Receives $26.57 Average PT from Brokerages

Alumis Inc. (NASDAQ:ALMS) has been given a consensus recommendation of “Buy” by the nine brokerages that are presently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $26.57.

Several equities analysts have recently commented on ALMS shares. Robert W. Baird assumed coverage on Alumis in a research note on Thursday, October 31st. They set an “outperform” rating and a $25.00 target price for the company. HC Wainwright reduced their price objective on shares of Alumis from $26.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Oppenheimer began coverage on shares of Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Finally, Baird R W raised Alumis to a “strong-buy” rating in a report on Thursday, October 31st.

Hedge Funds Weigh In On Alumis

Several institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new position in Alumis during the 3rd quarter worth $27,000. Wells Fargo & Company MN grew its position in shares of Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock worth $69,000 after acquiring an additional 3,823 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Alumis in the 4th quarter valued at about $79,000. MetLife Investment Management LLC acquired a new position in Alumis during the 3rd quarter valued at about $89,000. Finally, Marshall Wace LLP bought a new position in Alumis in the 4th quarter worth about $108,000.

Alumis Trading Up 0.8 %

NASDAQ:ALMS opened at $5.17 on Wednesday. Alumis has a one year low of $4.74 and a one year high of $13.53. The business’s 50-day simple moving average is $7.11 and its 200 day simple moving average is $9.69.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.